Adamed Pharma

What Adamed Pharma does

Adamed Pharma S.A. is a privately held Polish pharmaceutical-biotechnology company founded in 1986, headquartered at its Pieńków (Czosnów) manufacturing and R&D campus, with a registered share capital of 718,430,000 PLN. The company develops, manufactures, and distributes a diversified portfolio spanning prescription drugs, over-the-counter medications, dietary supplements, dermocosmetics, and medical devices across approximately 19 therapeutic areas and a portfolio of approximately 300 molecules, supported by 277 patents in pharmacy. Its products are commercially available in several dozen countries, distributed through 8 international representative offices in Poland, Ukraine, Czech Republic, Slovakia, Italy, Spain, Kazakhstan, Uzbekistan, and Vietnam, combined with traditional pharmacy, hospital, and wholesale channels.

The business model is built on two reinforcing revenue streams: (1) high-volume product sales of branded generics, OTC, supplements, and dermocosmetics into Polish and international markets, and (2) licensing and export revenue through its international offices and commercial partnerships across Europe, Central Asia, and Southeast Asia. Adamed is family-controlled by the Adamkiewicz family across three generations, with Dr. Małgorzata Adamkiewicz serving as Chair of the Supervisory Board and Dr. Karolina Adamkiewicz as Business Development Director. R&D focuses on original drug development and value-added drug development, with research collaborations including a partnership with Jagiellonian University on heme oxygenase-1 enzyme applications for wound healing. Manufacturing scale reached 103 million unit packages in 2025, and the company runs an integrated ecosystem of sub-brands (Adamed Discovery, Adamed Expert, ADAMED SmartUP, Fundacja Adamed) that support original R&D, healthcare professional engagement, and CSR programming.

Name

Adamed Pharma

Legal name

Adamed Pharma S.A.

Website

https://adamed.com

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Adamed Pharma is a Polish pharmaceutical-biotechnology company founded in 1986 that develops, manufactures, and distributes prescription drugs, OTC medications, supplements, dermocosmetics, and medical devices across approximately 19 therapeutic areas, selling through 8 international representative offices to patients in several dozen countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Oral Solid Dose (OSD) Generics (HLAIABAD), OTC & Consumer Health Distributors (HLAIAJAC), OTC Medicines & Consumer Health Products Distribution (CRAOAHAB)

Keywords

• Pharmaceutical drug development
• Prescription medication manufacturing
• Biotechnology research services
• Dermocosmetics product line
• Medical device distribution

Headquarters

HQ city

Warsaw

HQ country

Poland

HQ region

Europe

Offices10 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical product sales: Revenue generated from selling prescription drugs (Rx), over-the-counter medications (OTC), dietary supplements, dermocosmetics, and medical devices. Products address chronic civilization diseases across multiple therapeutic areas.
2. International licensing and exports: Revenue from licensing products to international markets through their 8 representative offices and commercial partnerships across Europe, Central Asia, and Southeast Asia.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Adamed Pharma develops, licenses, manufactures, markets, and distributes pharmaceutical products including prescription (Rx) drugs, over-the-counter (OTC) medications, dietary supplements, dermocosmetics, and medical devices. The company supports its product portfolio with proprietary R&D in original drug development and value-added formulations (generics/biosimilars) across approximately 19 therapeutic areas. Products are distributed in several dozen countries via 8 international representative offices.

Product overview

Adamed Pharma is a Polish pharmaceutical-biotechnological company with 40 years of experience, operating a diversified portfolio of products and services across 19 therapeutic areas with approximately 300 molecules in development. The company offers a comprehensive range of pharmaceutical products including prescription drugs (Leki na receptę), over-the-counter medications (Leki bez recepty), dietary supplements (Suplementy diety), dermocosmetics (Dermokosmetyki), and medical devices (Wyroby medyczne). The product portfolio is supported by a robust R&D infrastructure focusing on original drug development (Rozwój leków oryginalnych) and value-added drug development (Rozwój leków z wartością dodaną). With 277 patents in pharmacy and 103 million unit packages produced in 2025, the company maintains significant manufacturing capabilities serving patients in dozens of countries worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• Fundacja Adamed: Adamed Foundation - CSR and social programs
• ADAMED SmartUP
• Adamed dla Seniora
• Adamed Expert
• Adamed Discovery
• Adamed Expert Fundacja

Products and services

• Prescription Drugs (Leki na receptę) Prescription medications developed and manufactured by Adamed Pharma for the treatment of chronic civilization diseases across multiple therapeutic areas, distributed to physicians, pharmacies, and hospitals.
• Over-the-Counter Drugs (Leki bez recepty) Non-prescription medications available directly to consumers through pharmacies for self-medication of common health conditions.
• Dietary Supplements (Suplementy diety) Nutritional supplements designed to complement the diet and support overall health and wellness, available to consumers.
• Dermocosmetics (Dermokosmetyki) Skincare and cosmetic products developed with pharmaceutical-grade formulations for dermatological applications.
• Medical Devices (Wyroby medyczne) Medical devices and equipment designed for diagnosis, treatment, or monitoring of medical conditions.
• Original Drug Development (Rozwój leków oryginalnych) Research and development of novel pharmaceutical compounds and original medications based on proprietary Polish scientific research and 277 patents.
• Value-Added Drug Development (Rozwój leków z wartością dodaną) Development of improved versions of existing medications with enhanced therapeutic value or delivery mechanisms, including generics and biosimilars.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Jagiellonian UniversitycoreStrategic or Co-development PartnerResearch collaboration on heme oxygenase-1 (HO-1) enzyme research for wound healing applications. Joint publications in peer-reviewed journals including research on transgenic animal models and gene therapy approaches for diabetic wound treatment.
• Fundacja AdamedcoreOthersAdamed Foundation supporting educational programs, scientific initiatives, and community outreach. Part of the Adamed Group ecosystem.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Viatris: Global generics and specialty pharma formed from Mylan-Upjohn combination — directly competes with Adamed in European generics and biosimilars tender markets, though at substantially larger scale and global reach.
• Sandoz (Novartis): Global generics and biosimilars business, now independent of Novartis, with leading European generics footprint — comparable on portfolio mix but with materially larger R&D, manufacturing, and commercial infrastructure.
• Teva Pharmaceutical Industries: Global leader in generics and biosimilars with extensive European manufacturing and distribution — competes with Adamed in generic/added-value categories but operates at vastly larger scale and broader geographic reach.

Direct peers

• Gedeon Richter: Hungarian pharma group with branded generics, original R&D, and broad CEE/WEU/CIS distribution — directly comparable on European generics + innovator mix, manufacturing scale, and Eastern European geographic footprint.
• Krka: Slovenian pharmaceutical company with broad generic and value-added drug portfolio sold across CEE, Western Europe, and CIS markets — highly comparable on integrated manufacturing, generics emphasis, and CEE-to-WEU international expansion.
• Stada Arzneimittel: German-based generics and specialty pharma group with strong European footprint across Rx, OTC, and consumer health — directly comparable on value-added generics portfolio and European distribution, though larger scale than Adamed.
• Polfa Warszawa: Historic Polish state-linked pharmaceutical manufacturer producing Rx and OTC drugs — directly comparable on Polish-domestic manufacturing footprint, broad Rx/OTC product portfolio, and local market positioning.
• Polpharma: Poland's largest pharmaceutical manufacturer producing Rx, OTC and generics with strong CEE distribution — directly comparable to Adamed on geography, product mix (Rx/OTC/generics), and integrated R&D-manufacturing model.
• Zentiva: Central European-based generics and value-added pharmaceuticals company with operations across Czechia, Slovakia, Poland, Romania, and broader Europe — comparable on portfolio emphasis on value-added generics and CEE/WEU distribution.

Emerging players

• Alvotech: Iceland-based biosimilars-focused company with growing European commercial footprint — partial overlap with Adamed's biosimilar/value-added pharmaceutical strategy, particularly relevant for biosimilar pipeline comparison.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/adamed

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adamed Pharma